CUE vs IP · rev $9.3M vs P/E 43, $26.62B cap
Cue Biopharma (CUE) versus International Paper (IP) — a side-by-side from cached financials, not a winner call.
Cue Biopharma (CUE) is a biotechnology company listed on US.
International Paper (IP) is a packaging & containers company listed on US.
Latest reported CUE revenue for 2024-12-31 was $9.3M. Net income was -$40.7M. Revenue was up 69.2% from 2023-12-31 to 2024-12-31. CUE currently screens at market cap $59.5M.
IP does not have a complete income-statement cache yet.
CUE currently screens at market cap $59.5M. IP currently screens at market cap $26.62B and trailing P/E 43.1.
Not investment advice. Open the CUE and IP stock pages for the full models.
Not investment advice.